Abstract: Alzheimer’s disease (AD) is a common chronic and destructive disease. The early diagnosis of AD is difficult, thus the need for clinically applicable biomarkers development is growing rapidly. There are many methods to biomarker discovery and identification. In this review, we aim to summarize Mass spectrometry (MS)-based proteomics studies on AD and discuss thoroughly the methods to identify candidate biomarkers in cerebrospinal fluid (CSF) and blood. This review will also discuss the potential research areas on biomarkers
<div><p>Alzheimer’s disease is a neurodegenerative disorder accounting for more than 50% of cases of...
Abstract. Background: Alzheimer’s disease (AD) biomarkers are urgently needed for both early and acc...
Abstract. Biomarkers for neurodegenerative diseases should reflect the central pathogenic processes ...
Alzheimer’s disease (AD) is a common chronic and destructive disease. The early diagnosis of AD is d...
Alzheimer’s disease (AD) is the most common form of dementia in the elderly, and it is characterized...
With an increase in aging populations worldwide, age-related diseases such as Alzheimer’s disease (A...
Alzheimer’s disease (AD) is the most common type of dementia characterized by the progressive memory...
The complexity of Alzheimer’s disease (AD) and its long prodromal phase poses challenges for early d...
Purpose: The aim of this study is to identify the potential cerebrospinal fluid (CSF) biomarkers for...
Abstract. A blood-based protein biomarker, or set of protein biomarkers, that could predict onset an...
Alzheimer’s disease (AD) is the most common cause of dementia and is characterized by aggregation of...
Previous mass spectrometry analysis of cerebrospinal fluid (CSF) has allowed the identification of a...
Biomarkers for neurodegenerative diseases should reflect the central pathogenic processes of the dis...
The identification and validation of biomarkers for diagnosing Alzheimer's disease (AD) and other fo...
Blood-based biomarkers represent a less invasive and potentially cheaper approach for aiding Alzheim...
<div><p>Alzheimer’s disease is a neurodegenerative disorder accounting for more than 50% of cases of...
Abstract. Background: Alzheimer’s disease (AD) biomarkers are urgently needed for both early and acc...
Abstract. Biomarkers for neurodegenerative diseases should reflect the central pathogenic processes ...
Alzheimer’s disease (AD) is a common chronic and destructive disease. The early diagnosis of AD is d...
Alzheimer’s disease (AD) is the most common form of dementia in the elderly, and it is characterized...
With an increase in aging populations worldwide, age-related diseases such as Alzheimer’s disease (A...
Alzheimer’s disease (AD) is the most common type of dementia characterized by the progressive memory...
The complexity of Alzheimer’s disease (AD) and its long prodromal phase poses challenges for early d...
Purpose: The aim of this study is to identify the potential cerebrospinal fluid (CSF) biomarkers for...
Abstract. A blood-based protein biomarker, or set of protein biomarkers, that could predict onset an...
Alzheimer’s disease (AD) is the most common cause of dementia and is characterized by aggregation of...
Previous mass spectrometry analysis of cerebrospinal fluid (CSF) has allowed the identification of a...
Biomarkers for neurodegenerative diseases should reflect the central pathogenic processes of the dis...
The identification and validation of biomarkers for diagnosing Alzheimer's disease (AD) and other fo...
Blood-based biomarkers represent a less invasive and potentially cheaper approach for aiding Alzheim...
<div><p>Alzheimer’s disease is a neurodegenerative disorder accounting for more than 50% of cases of...
Abstract. Background: Alzheimer’s disease (AD) biomarkers are urgently needed for both early and acc...
Abstract. Biomarkers for neurodegenerative diseases should reflect the central pathogenic processes ...